ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
NAV as on 17-04-2025
₹ 39.27
▲0.9%
1D
Inception Returns
22.4%
/yr
Historical NAV & Returns
Absolute
▲
▼
6339 people have invested ₹ 4.9Cr in ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth in the last three months
About ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is an equity fund. This fund was started on 12 July, 2018. The fund is managed by Dharmesh Kakkad. The fund could potentially beat inflation in the long-run.
Key Parameters
- ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth has ₹4915 Cr worth of assets under management (AUM) as on Mar 2025 and is more than category average.
- The fund has an expense ratio 1.1.
Returns
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth has given a CAGR return of 22.41% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 21.02%, 23.46% and 26.57% respectively.
Holdings
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials, Financial Services. Its top holdings are Sun Pharmaceuticals Industries Ltd, Dr Reddy's Laboratories Ltd, Cipla Ltd, Divi's Laboratories Ltd, Aurobindo Pharma Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 20%For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefitDividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.
Investment objective of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
To generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. However there can be no assurance or guarantee that the investment objectives of the scheme would be achieved.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 100.00. ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth has no lock in period.
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth Overview
| Expense ratio | 1.11% |
Benchmark | BSE Healthcare TR INR |
| AUM | ₹4915 Cr |
| Inception Date | 12 July, 2018 |
| Min Lumpsum/SIP | ₹5000/₹100 |
Exit Load | 1.0% |
| Lock In | No Lock-in |
TurnOver | 49.46% |
| STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
INDmoney Rank for ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
Powered by IND quant engine
IND ranking is not available for this fund.
5Y returns in the top 25% of the category
3Y returns in the top 25% of the category
Larger AUM within category
No bad points found for this fund.
Trailing Returns
as on (17-Apr-25)
Fund Distribution
as on (31-Mar-25)
Large cap
42.6%
Small cap
29.2%
Mid cap
26.3%
Sector Allocation
Health
90.9%
Basic Materials
6.1%
Financial Services
3%
All changes are between Jan'25 and Mar'25
- This fund’s returns stands at 7.16% whereas the fund’s underlying benchmark Nifty 500 returns stands at 7.25% as on Mar'25
- This fund underperformed Nifty 500 by 0.09% in Mar'25
- AUM of the fund stands at 4.9K Cr as of Mar'25
- AUM increased by 303.2 Cr between Mar'25 and Feb'25
Top Stocks bought last month
Mankind Pharma Ltd's allocation increased from 2.85% to 3.5%
Windlas Biotech Ltd's allocation increased from 1.42% to 1.82%
Sun Pharmaceuticals Industries Ltd's allocation increased from 13.21% to 13.5%
Top Stocks sold last month
Cipla Ltd's allocation decreased from 9.55 % to 8.85 %
Divi's Laboratories Ltd's allocation decreased from 6.78 % to 6.71 %
Lupin Ltd's allocation decreased from 4.73 % to 4.73 %
Small Cap allocation has gone down from 29.9% to 29.2%
Mid Cap allocation has gone up from 25% to 26.3%
Large Cap allocation has gone down from 43.8% to 42.6%
Cash allocation has gone up from 1% to 1.7%
Top 3 Sectors in March were Health, Basic Materials & Financial Services
Mar'25
Health
91%
Basic Materials
6%
Financial Services
3%
Feb'25
Health
91%
Basic Materials
6%
Financial Services
3%
Holdings | Weight% | 1M Change | |
|---|---|---|---|
 Sun Pharmaceuticals Industries Ltd | 13.5% | 0% | |
 Dr Reddy's Laboratories Ltd | 8.95% | 4.1% | |
 Cipla Ltd | 8.85% | -3.6% | |
 Divi's Laboratories Ltd | 6.71% | 0% | |
 Aurobindo Pharma Ltd | 5.3% | 0% |
See all
Funds | 1Y Returns | 3Y Returns | 5Y Returns | Since Inception |
|---|---|---|---|---|
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | 21.02% | 23.46% | 26.57% | 22.41% |
 UTI Healthcare Fund-Growth Option- Direct | 22.13% | 20.25% | 23.63% | 16.18% |
 SBI Healthcare Opportunities Fund Direct Growth | 20.58% | 23.57% | 26.07% | 18.16% |
 LIC MF Healthcare Fund Direct Growth | 19.78% | 16.88% | 19.64% | 20.06% |
See all
Top Growth Drivers | 1M Return |
|---|---|
 Windlas Biotech Ltd | 22.3% |
 Aurobindo Pharma Ltd | 2% |
Loading...
We are taking more time than usual
Dharmesh Kakkad
Fund Manager of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth, since 2 May 2020
Top funds managed
Fund House
ICICI Prudential Asset Management Company Limited
Total Schemes
Total AUM
₹8.04L Cr
as on 31-Mar-2025
Address
ICICI Prudential Asset Mgmt.Company Limited,3rd Floor, Hallmark Business Plaza,,Sant Dyaneshwar Marg,,Bandra (East)
Phone
+912226428000
Website
investor.helpdesk@hdfcbank.com
Mutual Fund Insights
Over the last 3 months, this fund has increased expense ratio by 3.7% moving from 1.07 to 1.11.
Over the last 1 month, this fund has experienced a 6.6% growth in AUM moving from 4.61K Cr to 4.91K Cr.
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.11% which is lower than the category average expense ratio of 1.41%.
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 29.31% return, outperforming this fund by 8.29%.
In the last 5 years, this fund has outperformed all funds in its category.
In the last 3 years, SBI Healthcare Opportunities Fund Direct Growth has given 23.57% return, outperforming this fund by 0.11% per annum.
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 22.41% since inception which is more than its category average return of 17.06%
Fund Allocations
This fund has an allocation of 98.28% in Equity, 0% in Debt and 1.72% in Cash related instruments
AUM size ₹4915 Cr
This fund has AUM of ₹4915 Cr which is more than its category average of ₹ 1821 Cr
Expense Ratio 1.11%
This fund has an expense ratio of 1.11% which is less than its category average expense ratio of 1.44%
Most Popular Comparisons
- Compare
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D FundVs
Nippon India Pharma Fund Direct Growth
- Compare
- ICICI Prudential Pharma Healthcare and Diagnostics P.H.D FundVs
SBI Healthcare Opportunities Fund Direct Growth
- Compare
- ICICI Prudential Pharma Healthcare and Diagnostics P.H.D FundVs
DSP Healthcare Fund Direct Growth
- Compare
- ICICI Prudential Pharma Healthcare and Diagnostics P.H.D FundVs
Mirae Asset Healthcare Fund Direct Growth
- Compare
- ICICI Prudential Pharma Healthcare and Diagnostics P.H.D FundVs
UTI Healthcare Fund Direct Growth
Frequently Asked Questions for ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
The current NAV of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is ₹39.27 as on 17-Apr-2025.
Existing (Absolute + CAGR) as on 17-Apr-2025.
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 4% | 4% |
6 Month Returns | -5.71% | -5.71% |
1 Year Returns | 21.02% | 21.02% |
3 Years Returns | 88.16% | 23.46% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
1.11% as on March 2025
₹4915 Cr as on March 2025
Sun Pharmaceuticals Industries Ltd(13.5%), Dr Reddy's Laboratories Ltd(8.95%), Cipla Ltd(8.85%), Divi's Laboratories Ltd(6.71%), Aurobindo Pharma Ltd(5.3%) as on March 2025
Health(89.38%), Basic Materials(5.98%), Financial Services(2.92%) as on March 2025
The alpha ratio for the ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | 1.84 | 3.61 | 3.24 |
As on March 2025
The alpha for ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is calculated against BSE Healthcare TR INR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | 1 | 0.93 | 0.96 |
As on March 2025
The Beta for ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is calculated with BSE Healthcare TR INR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | 0.71 | 1 | 1.25 |
As on March 2025
The sharpe ratio for ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is calculated with BSE Healthcare TR INR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth | 20.2 | 16.26 | 19.59 |
As on March 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.81 as on March 2025. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 1.05 as on March 2025. It tells the consistency of the fund in generating superior risk-adjusted performance
Dharmesh Kakkad is the fund manager of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
The Exit load of ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth is 1%